Influence of Adamantilbromphenylamine on Parameters of Immunity and Symptoms of Asthenia in Patients with Non-Psychotic Mental Disorders

Cover Page

Abstract


Objective: Our aim was to assess effect of antiasthenic drug adamantilbromphenylamine on the immune system and symptoms of asthenia in patients with non-psychotic mental disorders and to reveal possible criteria for prediction of treatment efficiency.

Methods: Uncontrolled study with interrupted time series was carried out. According to efficiency of treatment patients were divided into two groups (group 1 (n =21) — very much improved and much improved; group 2 (n =9) — minimally improved). Adamantilbromphenylamine was administered to patients as a monotherapy 100 mg a day for 28 days. Examination was conducted before and after therapy. Severity of asthenic symptoms according to MFI-20 scale was identified; cellular and humoral immunity parameters, mitogen-induced production of interleukins (IL) 1β and IL 4 by immunocompetent cells of patients were assessed.

Results: 30 patients with non-psychotic mental disorders with predominance of asthenic symptomatology in clinical picture of the disease were examined. Before therapy every proband had over 60 points across 5 items of MFI-20 scale. As compared with control decrease of number of lymphocytes of CD3+-, HLA-DR+, CD16+-phenotypes; increase in the ratio of CD4+/CD8+; concentration of serum IgМ; phagocytic activity of neutrophils were revealed. In the end of therapy in group 1, sum total of points of asthenia decreased up to 26 (23–37) (p <0.001); in group 2 — up to 57 (47–61). Only in group 1 positive dynamic of immune parameters was revealed. It was shown that baseline level of proinflammatory cytokine IL 1β in group with apparent therapeutic effect of the drug was reliably lower, than in group with minimal improvement (p =0.005). These differences remained also after course of therapy (p =0.042).

Conclusion: Interrelationship of clinical-immunological effect of adamantilbromphenylamine has been revealed; intensity of production of IL 1β may be considered as a criterion of prognosis of efficiency of treatment with adamantilbromphenylamine in patients with non-psychotic mental disorders


T. P. Vetlugina

Mental Health Research Institute

Author for correspondence.
Email: vetlug@mail.tomsknet.ru

Russian Federation Tomsk

V. B. Nikitina

Mental Health Research Institute

Email: valentina08@sibmail.com

Russian Federation Tomsk

S. A. Sergeeva

Mental Health Research Institute

Email: sa-sergeeva@inbox.ru

Russian Federation Tomsk

M. M. Axenov

Mental Health Research Institute

Email: max1957@sibmail.com

Russian Federation Tomsk

O. A. Lobacheva

Mental Health Research Institute

Email: oalobacheva@sibmail.com

Russian Federation Tomsk

D. N. Savochkina

Mental Health Research Institute

Email: kokodasha@yandex.ru

Russian Federation Tomsk

E. M. Epanchintseva

Mental Health Research Institute

Email: klinika.stat@sibmail.com

Russian Federation Tomsk

N. A. Bokhan

Mental Health Research Institute

Email: bna909@gmail.com

Russian Federation Tomsk

  1. Aleksandrovskii Yu.A. Treatment of patients with asthenic disorders drug tanakan. Rossiiskii psikhiatricheskii zhurnal = Russian journal of psychiatry. 1999;1:24–27.
  2. Semke V.Ya. Preventivnaya psikhiatriya [Preventive Psychiatry]. Tomsk, Izd-vo TGU, 1999. 402 p.
  3. Smulevich A.B., Dubnitskaya E.B. Asthenia and comorbid psychiatric disorders. Psikhiatriya i psikhofarmakoterapiya = Psychiatry and pharmacotherapy. 2009;11(4):4–7.
  4. Neznamov G.G., Syunyakov S.A., Teleshova E.S., Chumakov D.V., Reutova M.A., Syunyakov T.S., Mametova L.E., Dorofeeva O.A., Grishin S.A. New drug with stimulant and anxiolytic properties in the treatment of neurasthenia Ladasten (the results of comparative clinical studies with placebo). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of neurology and psychiatry. 2009;109(5):20–26.
  5. Aktual'nye problemy neiroimmunopatologii. Rukovodstvo. Pod red. G.N. Kryzhanovskogo, S.V. Magaevoi, S.G. Morozova [Actual Problems of Neuro- and Immunopatology. Guidelines. Ed. by G,N, Kryzhanovsky, S.V. Magaeva, S.G. Morozov]. Moscow, Genius Media, 2012. 423 p.
  6. Vetlugina T.P., Nevidimova T.I. Nikitina V.B., Lobacheva O.A., Bokhan N.A., Semke V.Ya. Pathogenetic substantiation technologies immune for mental disorders and diseases of addiction. Sibirskii vestnik psikhiatrii i narkologii = Siberian herald of psychiatry and addiction. 2013;1:7–12.
  7. Jones K.A., Thomsen C. The role of the innate immune system in psychiatric disorders. Mol. Cell Neurosci. 2013; 53: 52–62.
  8. Smets E.M.A., Garssen B., Bonke B., De Haes J.C.J.M. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995; 39 (3): 315–325.
  9. Smulevich A.B., Andryushchenko A.V., Beskova D.A. A new approach to the treatment of neurasthenia and asthenia somatogenic (results of a multicenter study of efficacy and safety of ladasten). Psikhiatriya i psikhofarmakoterapiya = Psychiatry and pharmacotherapy. 2009;11(1):18–26.
  10. Voznesenskaya T.G., Fokina N.M., Yakhno N.N. Treatment of asthenic disorders in patients with psycho-vegetative syndrome (results of a multicenter study of efficacy and tolerability of ladasten). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of neurology and psychiatry. 2010;110(5):17–26.
  11. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publNO (Adm) 76–338. Bethesda MD: National Institute of Mental Health. 1976. P. 217–222.
  12. ВVukolov E.A. Osnovy statisticheskogo analiza. Praktikum po statisticheskim metodam i issledovaniyu operatsii s ispol'zovaniem paketov Statistica i Excel [Based on statistical analysis. Workshop on statistical methods and operations research using the package Statistica and Excel]. Moscow, FORUM, 2008. 464 p.
  13. Rebrova O.Yu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. The use of the application package STATISTICA]. Moscow, MediaSfera, 2002. 312 p.
  14. Syunyakov S.A., Grishin S.A., Teleshova E.S., Neznamov G.G., Seredenin S.B. The results of a pilot clinical study of Ladasten. Eksperimental'naya i klinicheskaya farmakologiya = Experimental and clinical pharmacology. 2006;69(4):10–15.
  15. Mirzoyan R.S., Gan’Shina T.S., Maslennikov D.V., Kovalev G.I., Zimin I.A., Pyatin B.M., Avdyunina N.I., Kukhtarova A.M., Khostikyan N.G., Meliksetyan V.S., Alikhanyan C.B., Mirzoyan N.R. Сerebrovascular and neuroprotective effects of adamantane derivative. Biomed. Res. Int. 2014; 2014: 586501.
  16. Tallerova A.V., Kovalenko L.P., Kuznetsova O.S., Durnev A.D., Seredenin S.B. Сorrecting effect of ladasten on variations in the subpopulation composition of t lymphocytes in c57bl/6 mice on the experimental model of an anxious depressive state. Bull. Exp. Biol. Med. 2014; 156 (3): 335–337.
  17. Oliynyk S., Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol. Ther. (Seoul). 2012; 20(5): 446–456.
  18. Kundashev U.K., Zurdinov A.Z., Morozov I.S., Barchukov V.G. Pharmacological correction of adaptive responses of the cardiovascular and central nervous systems of the workers in the mountain mine in shifts of work organization. Mediko-biologicheskie i sotsial'no-psikhologicheskie problemy bezopasnosti v chrezvychainykh situatsiyakh = Medico-biological and socio-psychological problems of safety in emergency situations. 2013;4:76–81.
  19. Kundashev U.K., Zurdinov A.Z., Barchukov V.G. Possibilities of pharmacological correction of adaptive responses of the human body in the short-term movements of the midlands in the highlands. Eksperimental'naya i klinicheskaya farmakologiya = Experimental and clinical pharmacology. 2014; 77 (9): 32–37.
  20. Andryushchenko A.V., Smulevich A., Syrkin A.L., Beskova D.A., Kopylov F.Yu., Aripov M.A., Romanov D.V. Treatment of asthenic disorders in patients with cardiovascular disease using the drug Ladasten (the results of a multicenter study "Standards"). The results of a pilot clinical study of Ladasten. Psikhicheskie rasstroistva v obshchei meditsine = Mental disorders in general medicine. 2011;1:4–13.
  21. Kanaeva L.S., Avedisova A.S. Prognostic role of clinical and social factors in evaluating the effectiveness of drug therapy in patients with non-psychotic depression. Farmateka = Pharmateca. 2014; 10-3: 45–52.
  22. Nikitina V.B. Role of immune mechanisms in the clinical dynamics of post-traumatic stress disorder. Sibirskii vestnik psikhiatrii i narkologii = Siberian herald of psychiatry and addiction. 2009; 3: 14–16.
  23. Morozov I.S., Pukhova G.S., Avdulov N.A., Sergeeva S.A., Spasov A.A, Iezhitsa I.N. The mechanisms of the neurotropic action of bromantan. Eksp. Klin. Farmakol. 1999; 62 (1): 11–14.
  24. Zimin I.A., Abaimov D.A., Budygin E.A., Zolotarev Yu.A., Kovalev G.I. Participation of dopamine and serotonergic systems in the brain in the implementation of psychopharmacological effects of Ladasten and Sidnokarb. Eksperimental'naya i klinicheskaya farmakologiya = Experimental and clinical pharmacology. 2010; 73 (2): 2–5.
  25. Idova G.V., Alperina E.L., Cheido M.A. Contribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: evidence from pharmacological analysis. Int. Immunopharmacol. 2012; 12 (4): 618–625.
  26. Tallerova A.V., Kovalenko L.P., Durnev A.D., Seredenin S.B. Influence of Ladasten on the level of cytokine markers of inflammation and behavior of mice in the simulation depressive-like syndrome. Byulleten' eksperimental'noi biologicheskoi meditsiny = Bulletin of experimental biological medicine. 2011; 152 (7): 65–67.
  27. Kitaev M.I., Samanchina B.T., Mainazarova E.S., Alymkulova A.D., Alymbaeva M.D. Pro-inflammatory cytokines and opposition in chronic obstructive pulmonary disease. Vestnik KRSU = Bulletin of KRSU. 2012; 12 (1): 110–113.
  28. Reale M., de Angelis F., di Nicola M., Capello E., di Ioia M., Luca G., Lugaresi A., Tata A.M. Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing Remitting Multiple Sclerosis Patients. Int. J. Mol. Sci. 2012; 13 (10): 12656–1264.

Views

Abstract - 44

PDF (Russian) - 5

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies